The standard maximum duration for Keytruda (pembrolizumab) in metastatic lung cancer is 2 years, or roughly 35 treatment cycles. The FDA approves its use until disease progression, unacceptable side effects, or up to 24 months, whichever comes first. In practice, many patients stop well before that 2-year mark, and a smaller number may continue beyond it under specific circumstances.
The 2-Year Treatment Cap
Keytruda’s FDA-approved label for metastatic non-small cell lung cancer (NSCLC) sets a clear ceiling: treatment continues until the cancer progresses, side effects become too severe, or 24 months have passed. This isn’t arbitrary. The major clinical trials that established Keytruda as a frontline treatment used this same 2-year limit, and the long-term data support it.
A large nationwide study published in The Lancet Regional Health found that continuing Keytruda beyond 2 years offered no survival advantage over stopping at the 2-year mark. The researchers concluded that a fixed 2-year duration is safe, confirming what many oncologists already suspected: for patients who respond well, 2 years appears to be enough to get the full benefit.
Most Patients Don’t Reach 2 Years
While 2 years is the upper limit, many patients stop treatment earlier. In the landmark KEYNOTE-024 trial, which studied patients whose tumors had high levels of a protein called PD-L1, only about 26% of patients (39 out of 151) completed the full 35 cycles. The rest stopped sooner, most commonly because the cancer progressed or side effects became problematic.
How long you stay on treatment depends heavily on your tumor’s biology. Patients whose tumors express very high levels of PD-L1 (90% or above) stayed on treatment for a median of about 6 months. Those with somewhat lower expression (50% to 89%) had a median treatment duration of just 3.2 months. These numbers reflect the reality that treatment continues only as long as it’s working and tolerable.
What Happens After You Stop at 2 Years
The encouraging news is that patients who make it to the 2-year finish line tend to do very well afterward. In the KEYNOTE-024 five-year follow-up, 82 out of 100 patients who completed 2 years of Keytruda were still alive three years later. Nearly half of those patients were alive with no signs of cancer progression and no need for additional treatment. The immune system, once activated by Keytruda, can continue controlling the cancer on its own for years.
If the cancer does return after stopping, restarting Keytruda is sometimes an option, though this is evaluated on a case-by-case basis.
When Treatment Continues Beyond Progression
Immunotherapy works differently than chemotherapy. Sometimes a scan shows the tumor growing slightly before the immune response kicks in and starts shrinking it. This phenomenon, called pseudoprogression, means that initial imaging showing growth doesn’t always signal true treatment failure.
Some oncologists choose to continue Keytruda for at least a few more cycles after scans suggest progression, particularly in patients who are otherwise feeling well. A real-world study found that continuing Keytruda after initial progression was an independent predictor of longer survival. Certain patterns make this approach more reasonable: when only one or two spots are growing (oligoprogression), when there are no new tumors in major organs, or when the patient’s overall physical condition remains good. This decision requires careful judgment, balancing the possibility that the immune system needs more time against the risk of continuing an ineffective treatment.
Duration for Early-Stage Lung Cancer
The 2-year cap applies to metastatic (stage IV) disease. For earlier-stage lung cancer that can be surgically removed, the treatment schedule looks different. Keytruda is given for about 12 weeks before surgery as neoadjuvant therapy, followed by up to 39 weeks after surgery as adjuvant therapy. That adds up to roughly a year of total treatment. Insurance coverage mirrors this structure, covering the pre-surgery and post-surgery phases separately.
Side Effects That Can Cut Treatment Short
Keytruda works by releasing the brakes on your immune system, which means it can sometimes trigger the immune system to attack healthy tissues. These immune-related side effects are the most common reason patients stop treatment before the cancer progresses.
Mild to moderate reactions, like skin rashes, fatigue, or thyroid problems, can often be managed while staying on treatment. Thyroid issues in particular are common and usually handled with hormone replacement without needing to stop Keytruda. More serious reactions require pausing or permanently stopping treatment. Inflammation of the lungs (pneumonitis) is one that oncologists watch for closely in lung cancer patients, since it can mimic worsening disease on scans.
The general guideline is that severe (grade 4) immune reactions require permanently discontinuing Keytruda, with one exception: hormone-related side effects that can be fully controlled with replacement medication. Certain rare but serious skin reactions, like blistering disorders, also require stopping treatment regardless of severity grade.
Insurance Coverage and the 24-Month Limit
Major insurers, including Medicare plans, generally cover Keytruda for metastatic lung cancer until disease progression, unacceptable toxicity, or 24 months. Coverage aligns closely with the FDA label, so the 2-year cap applies to insurance as well. For adjuvant treatment after surgery, coverage typically extends up to 12 months. If your oncologist recommends continuing beyond these windows, prior authorization and additional documentation may be required.